BOULDER, Colo., Oct. 28, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the first quarter of fiscal 2014 and hold a conference call to discuss those results on Thursday, October 31, 2013. Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call.
(Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO)
Conference Call Information |
|
Date: |
Thursday, October 31, 2013 |
Time: |
9:00 a.m. eastern time |
Toll-Free: |
(877) 261-8990 |
Toll: |
(847) 619-6441 |
Pass Code: |
35902809 |
Webcast, including Replay and Conference Call Slides: |
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company and currently expects significant progress toward generating data to support our upcoming Phase 3 / pivotal trial decisions. Novartis began Phase 3 trials evaluating Array-invented MEK162 in patients with NRAS-mutant melanoma in July 2013 and in patients with BRAF-mutant melanoma in October 2013. In addition, Array began a Phase 3 trial evaluating MEK162 in patients with low-grade serous ovarian cancer under the license agreement with Novartis in June 2013. AstraZeneca began a pivotal trial with Array-invented selumetinib in patients with thyroid cancer in May 2013 and began a Phase 3 trial in patients with non-small cell lung cancer in October 2013. Two other wholly-owned drugs, ARRY-520 and ARRY-614, are also approaching Phase 3 or pivotal trial decisions which are expected by the end of 2013. For more information on Array, please go to www.arraybiopharma.com.
CONTACT: |
Tricia Haugeto |
Array BioPharma Inc. |
|
(303) 386-1193 |
|
SOURCE Array BioPharma Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article